These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39403452)

  • 1. Prognostic value of immune-inflammatory and nutrition indicators in non-metastatic nasopharyngeal carcinoma with negative plasma Epstein-Barr virus DNA.
    Weng Y; Wu L; Li Y; Wang J; Wu Z; Hong X; Liu X; Lai J; Lu J; Qiu S
    Ther Adv Med Oncol; 2024; 16():17588359241286489. PubMed ID: 39403452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic efficacy of the combination of the pretreatment systemic Immune-Inflammation Index and Epstein-Barr virus DNA status in locally advanced Nasopharyngeal Carcinoma Patients.
    Xiong Y; Shi LL; Zhu LS; Ding Q; Ba L; Peng G
    J Cancer; 2021; 12(8):2275-2284. PubMed ID: 33758605
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.
    Yuan X; Yang H; Zeng F; Zhou S; Wu S; Yuan Y; Cui L; Feng H; Lin D; Chen Z; Liu X; Chen J; Wang F
    BMC Cancer; 2022 Aug; 22(1):858. PubMed ID: 35932022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.
    Kong FF; Pan GS; Du CR; Ni MS; Zhai RP; He XY; Shen CY; Lu XG; Hu CS; Ying HM
    Radiother Oncol; 2023 Aug; 185():109721. PubMed ID: 37244356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.
    Li WZ; Wu HJ; Lv SH; Hu XF; Liang H; Liu GY; Lu N; Bei WX; Lv X; Guo X; Xia WX; Xiang YQ
    JAMA Netw Open; 2021 Sep; 4(9):e2124721. PubMed ID: 34554238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma.
    Wu S; Yuan X; Huang H; Li Y; Cui L; Lin D; Lu W; Feng H; Chen Z; Liu X; Tan J; Wang F
    BMC Cancer; 2023 Dec; 23(1):1217. PubMed ID: 38066499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
    Dong H; Huang Z; Yang D; Li Z; Huang H; Meng Z; Qin Y; Kang M
    BMC Cancer; 2023 Jul; 23(1):673. PubMed ID: 37464319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of Pre-Treatment CALLY Score Combined with EBV-DNA Levels for Prognostication in Non-Metastatic Nasopharyngeal Cancer Patients: A Clinical Perspective.
    Jiang T; Sun H; Xu T; Xue S; Xia W; Xiao X; Wang Y; Guo L; Lin H
    J Inflamm Res; 2024; 17():3353-3369. PubMed ID: 38803689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
    Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
    Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
    Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
    Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating Postradiotherapy MRI-Detected Lymph Node Necrosis and Pre- and Posttreatment Epstein-Barr Virus-DNA for Risk Stratification in Nasopharyngeal Carcinoma.
    Cao D; Li S; Li H; Liu L; Wang X; Quan T
    J Magn Reson Imaging; 2023 Jul; 58(1):108-119. PubMed ID: 36326089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic model on overall survival in elderly nasopharyngeal carcinoma patients: a recursive partitioning analysis identifying pre-treatment risk stratification.
    Li Y; Weng Y; Huang Z; Pan Y; Cai S; Ding Q; Wu Z; Chen X; Lu J; Hu D; Qiu S
    Radiat Oncol; 2023 Jun; 18(1):104. PubMed ID: 37353800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
    Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
    JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
    Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
    Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A scoring system based on inflammatory and nutritional indicators to predict the long-term survival of patients with non-metastatic nasopharyngeal carcinoma.
    Fang WN; Wu HX; Wu ZP; Fei ZD; Zhao D; Chen F; Lin C; Ma LQ
    Sci Rep; 2024 Aug; 14(1):20229. PubMed ID: 39215059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of pan-immune-inflammation value (PIV) in nasopharyngeal carcinoma patients.
    Zhang N; Hou T; Zhang S; Ling J; Jiang S; Xie Y; Liu X; Hu C; Feng Y
    Heliyon; 2024 Jan; 10(2):e24804. PubMed ID: 38312571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma.
    Guo J; He Y; Lin C; Jiang Q; Xing HW; Zhang YC; Shen GZ; Lin HX; Guo L; Yang Q
    Oral Oncol; 2023 Nov; 146():106574. PubMed ID: 37741017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.